PPSV-23

PreclinicalBiologic

UUniversity of Colorado, Denver

PPSV-23 is one of 8 biologic programs targeting Vaccine Response. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Vaccine ResponseUnknown status

Vaccine ResponsePreclinical

Unknown status

Competition

Competitive Landscape

7 competitors in Vaccine Response

#DrugCompanyPhaseTrials

Fluzone

GSK

Phase 2

2 2

Quadrivalent Seasonal Influenza Vaccine

EEmory University

Phase 3

2 3

Fluad

Moderna

Phase 2

3 4

Thymalfasin

SSciClone Pharmaceuticals

Phase 1

1 5

Menacwy Liquid

GSK

Preclinical

1 6

Typhim Vi Vaccine

NNicole Stoffel

Preclinical

1 7

PCV-13

UUniversity of Colorado, Denver

Preclinical

1 8

PPSV-23

UUniversity of Colorado, Denver

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Vaccine Response1 trial

Mechanisms of Impaired HIV-associated B Cell and Pneumococcal Vaccine Responses

Unknown status·UUniversity of Colorado, Denver·N/A·NCT02012309·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for PPSV-23. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PPSV-23 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PPSV-23. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Colorado, Denver company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: UUniversity of Colorado, Denver

PPSV-23

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Vaccine Response1 trial

References

Drug Info

Quick Facts

Related News